These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
286 related articles for article (PubMed ID: 33611192)
1. Design, synthesis, and biological evaluation of 4-benzoylamino-1H-pyrazole-3-carboxamide derivatives as potent CDK2 inhibitors. Lin T; Li J; Liu L; Li Y; Jiang H; Chen K; Xu P; Luo C; Zhou B Eur J Med Chem; 2021 Apr; 215():113281. PubMed ID: 33611192 [TBL] [Abstract][Full Text] [Related]
2. Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition. Maher M; Kassab AE; Zaher AF; Mahmoud Z Anticancer Agents Med Chem; 2019; 19(11):1368-1381. PubMed ID: 31038080 [TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, antineoplastic activity of new pyrazolo[3,4-d]pyrimidine derivatives as dual CDK2/GSK3β kinase inhibitors; molecular docking study, and ADME prediction. Nemr MTM; Elshewy A; Ibrahim ML; El Kerdawy AM; Halim PA Bioorg Chem; 2024 Sep; 150():107566. PubMed ID: 38896936 [TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of certain CDK2 inhibitors based on pyrazole and pyrazolo[1,5-a] pyrimidine scaffold with apoptotic activity. Ali GME; Ibrahim DA; Elmetwali AM; Ismail NSM Bioorg Chem; 2019 May; 86():1-14. PubMed ID: 30682722 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of Benzamide-Chalcone Derivatives as EGFR/CDK2 Inhibitor: Synthesis, In-Vitro Inhibition, and Molecular Modeling Studies. Joshi A; Bhojwani H; Wagal O; Begwani K; Joshi U; Sathaye S; Kanchan D Anticancer Agents Med Chem; 2022; 22(2):328-343. PubMed ID: 33858315 [TBL] [Abstract][Full Text] [Related]
7. Synthesis of a new series of pyrazolo[1,5-a]pyrimidines as CDK2 inhibitors and anti-leukemia. Almehmadi SJ; Alsaedi AMR; Harras MF; Farghaly TA Bioorg Chem; 2021 Dec; 117():105431. PubMed ID: 34688130 [TBL] [Abstract][Full Text] [Related]
8. Synthesis, in vitro anticancer activity and in silico studies of certain pyrazole-based derivatives as potential inhibitors of cyclin dependent kinases (CDKs). Mohammed EZ; Mahmoud WR; George RF; Hassan GS; Omar FA; Georgey HH Bioorg Chem; 2021 Nov; 116():105347. PubMed ID: 34555628 [TBL] [Abstract][Full Text] [Related]
9. Molecular docking approach for the design and synthesis of new pyrazolopyrimidine analogs of roscovitine as potential CDK2 inhibitors endowed with pronounced anticancer activity. Hamed OA; Abou-Elmagd El-Sayed N; Mahmoud WR; F Elmasry G Bioorg Chem; 2024 Jun; 147():107413. PubMed ID: 38696844 [TBL] [Abstract][Full Text] [Related]
10. Mechanistic selectivity investigation and 2D-QSAR study of some new antiproliferative pyrazoles and pyrazolopyridines as potential CDK2 inhibitors. Hassan GS; Georgey HH; Mohammed EZ; George RF; Mahmoud WR; Omar FA Eur J Med Chem; 2021 Jun; 218():113389. PubMed ID: 33784602 [TBL] [Abstract][Full Text] [Related]
11. Novel oxindole/benzofuran hybrids as potential dual CDK2/GSK-3β inhibitors targeting breast cancer: design, synthesis, biological evaluation, and Eldehna WM; Al-Rashood ST; Al-Warhi T; Eskandrani RO; Alharbi A; El Kerdawy AM J Enzyme Inhib Med Chem; 2021 Dec; 36(1):270-285. PubMed ID: 33327806 [TBL] [Abstract][Full Text] [Related]
12. A study on MAPK/ERK and CDK2-Cyclin-E signal switch "on and off" in cell proliferation by bis urea derivatives of 1, 4-Diisocyanatobenzene. Nagalakshmamma V; Venkataswamy M; Pasala C; Uma Maheswari A; Thyaga Raju K; Nagaraju C; Chalapathi PV Bioorg Chem; 2021 Jul; 112():104940. PubMed ID: 33965780 [TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and biological evaluation of N-((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)-1,3-diphenyl-1H-pyrazole-4-carboxamides as CDK1/Cdc2 inhibitors. Ganga Reddy V; Srinivasa Reddy T; Lakshma Nayak V; Prasad B; Reddy AP; Ravikumar A; Taj S; Kamal A Eur J Med Chem; 2016 Oct; 122():164-177. PubMed ID: 27344493 [TBL] [Abstract][Full Text] [Related]
14. Imidazo[1,2-c]pyrimidin-5(6H)-one inhibitors of CDK2: Synthesis, kinase inhibition and co-crystal structure. Jansa J; Jorda R; Škerlová J; Pachl P; Peřina M; Řezníčková E; Heger T; Gucký T; Řezáčová P; Lyčka A; Kryštof V Eur J Med Chem; 2021 Apr; 216():113309. PubMed ID: 33711765 [TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFR Gaber AA; Bayoumi AH; El-Morsy AM; Sherbiny FF; Mehany ABM; Eissa IH Bioorg Chem; 2018 Oct; 80():375-395. PubMed ID: 29986185 [TBL] [Abstract][Full Text] [Related]
16. New thiazol-hydrazono-coumarin hybrids targeting human cervical cancer cells: Synthesis, CDK2 inhibition, QSAR and molecular docking studies. Abd El-Karim SS; Syam YM; El Kerdawy AM; Abdelghany TM Bioorg Chem; 2019 May; 86():80-96. PubMed ID: 30685646 [TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of pyrimidine derivatives as novel CDK2 inhibitors that induce apoptosis and cell cycle arrest in breast cancer cells. Wang Y; Chen Y; Cheng X; Zhang K; Wang H; Liu B; Wang J Bioorg Med Chem; 2018 Jul; 26(12):3491-3501. PubMed ID: 29853338 [TBL] [Abstract][Full Text] [Related]
18. Discovery of 3,6-disubstituted pyridazines as a novel class of anticancer agents targeting cyclin-dependent kinase 2: synthesis, biological evaluation and in silico insights. Sabt A; Eldehna WM; Al-Warhi T; Alotaibi OJ; Elaasser MM; Suliman H; Abdel-Aziz HA J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1616-1630. PubMed ID: 32781872 [TBL] [Abstract][Full Text] [Related]
19. Discovery of New Pyrazolopyridine, Furopyridine, and Pyridine Derivatives as CDK2 Inhibitors: Design, Synthesis, Docking Studies, and Anti-Proliferative Activity. Abdel-Rahman AA; Shaban AKF; Nassar IF; El-Kady DS; Ismail NSM; Mahmoud SF; Awad HM; El-Sayed WA Molecules; 2021 Jun; 26(13):. PubMed ID: 34206976 [TBL] [Abstract][Full Text] [Related]
20. Benzimidazole-oxindole hybrids: A novel class of selective dual CDK2 and GSK-3β inhibitors of potent anticancer activity. Abdel-Mohsen HT; Syam YM; Abd El-Ghany MS; Abd El-Karim SS Arch Pharm (Weinheim); 2024 Oct; 357(10):e2300721. PubMed ID: 39041665 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]